



INVESTOR IN PEOPLE

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

The Patent Office

Concept House

Cardiff Road 07 MAR 2003

Newport

South Wales

PCT

NP10 8QQ


PCT/GB 2003 / 0 0 0 2 5 3

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Andrew Gernsey

Dated

5 February 2003

BEST AVAILABLE COPY

THE PATENT OFFICE
G
25 JAN 2002
NEWPORT

The
Patent
Office

25JAN02 E690800-1 002973
P01/7700 0:00-0201679.8

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference

P16180

2. Patent application number

(The Patent Office will fill in this part)

0201679.8

25 JAN 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Asterion Limited
Firth Court
Western Bank
SHEFFIELD
S10 2TN
UK

Patents ADP number (if you know it)

8244857001

If the applicant is a corporate body, give the country/state of its incorporation

UK

4. Title of the invention

Polypeptide Variants

5. Name of your agent (if you have one)

Harrison Goddard Foote

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Belgrave Hall
Belgrave Street
LEEDS
LS2 8DD
UK

Patents ADP number (if you know it)

14571001 7631310002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

YES

POLYPEPTIDE VARIANTS

The invention relates to polypeptides which comprises more than two ligand binding domains of a cytokine wherein the domains are linked by a flexible linker which optionally comprises
5 a proteolytic cleavage site.

Ligands which interact with receptors to bring about a suitable biochemical response are known as agonists and those that prevent, or hinder, a biochemical response are known as antagonists. For example, and not by way of limitation, cell specific growth factors are
10 ligands that act as agonists and bind receptors located at the cell surface. Activation of the receptors by ligand-specific binding promotes cell proliferation via activation of intracellular signalling cascades that result in the expression of, amongst other things, cell-cycle specific genes, and the activation of quiescent cells to proliferate. Growth factors may also activate cellular differentiation.

15

A large group of growth factors, referred to as cytokines, are involved in a number of diverse cellular functions. These include, by example and not by way of limitation, modulation of the immune system, regulation of energy metabolism and control of growth and development. Cytokines which are secreted by lymphocytes are termed lymphokines (also known as
20 interleukins). Those secreted by monocytes and macrophages are termed monokines. Cytokines are also secreted by endocrine glands, (for example growth hormone (GH) by the pituitary gland), and adipose cells (for example leptin). Cytokines mediate their effects via receptors expressed at the cell surface on target cells.

25 Receptors of the cytokine receptor family possess a single transmembrane domain and lack intrinsic enzyme activity (Kishimoto *et al.*, 1994). Upon the binding of a cytokine to a cognate receptor, either receptor homo- or hetero-dimerisation or oligomerisation occurs. The receptor complex is internalised and signaling occurs through the activation of associated signaling cascades that include the Jak/Stat and Mapk pathways. Internalisation is followed by
30 a recycling step whereby the receptor molecule is regenerated for further use within the cell.

An example of the above is described with respect to GH and its binding to the GHR. This example is merely meant to be illustrative and not limiting and is an example of a cytokine which activates a signal transduction cascade by binding, dimerisation and internalisation of

the receptor:ligand complex. It is known that a single molecule of growth hormone (GH) associates with two receptor molecules (Cunningham *et al.*, 1991; de Vos *et al.*, 1992; Sundstrom *et al.*, 1996; Clackson *et al.*, 1998). This occurs through two unique receptor-binding sites on GH and a common binding pocket on the extracellular domain of two
5 receptors. Site 1 on the GH molecule has a higher affinity than site 2, and receptor dimerization is thought to occur sequentially with one receptor binding to site 1 on GH followed by recruitment of a second receptor to site 2.

The extracellular domain of the GHR exists as two linked domains each of approximately 100
10 amino acids (SD-100), the C-terminal SD-100 domain being closest to the cell surface and the N-terminal SD-100 domain being furthest away. It is a conformational change in these two domains that occurs on hormone binding with the formation of the trimeric complex GHR-GH-GHR. It has been proposed that ligand-driven receptor dimerization is the key event leading to signal activation (Cunningham *et al.*, 1991), triggering phosphorylation cascades
15 that include the Jak2/Stat5 pathway (Argetsinger & Carter-Su, 1996). Using confocal microscopy and Frequency Resonance Energy Transfer (FRET) it is known that there is very rapid internalisation of GHR after ligand binding and that internalisation and signaling are independent functions (Maamra *et al.*, 1999). Internalisation of the GHR-GH-GHR complex is followed by a recycling step whereby the receptor molecule is regenerated for further use
20 within the cell.

Examples of cytokines which are related to GH are leptin and erythropoietin (EPO). The leptin receptor and the EPO receptor share considerable structural homology to the GHR and require a similar dimerisation process to trigger signaling. Leptin suppresses appetite and leptin
25 resistance is associated with obesity. A leptin receptor antagonist will provide a treatment for anorexia nervosa. EPO excess causes polycythaemia which may be secondary to hypoxia (chronic lung disease), or primary in the case of polycythaemia rubra vera (a disorder of excess red blood cells). An EPO antagonist will provide a therapy for polycythaemia.

30 The disorders of acromegaly and gigantism result from an excess of growth hormone, usually due to pituitary tumours. A drug currently under trial is the pegylated GH antagonist B2036, designed using recently acquired knowledge of the molecular structure of the GHR. Unfortunately, high levels of B2036 are required to antagonise GH action with drug levels over a 1000 times higher than endogenous GH levels.

The invention relates, *inter alia*, to the provision of oligomeric polypeptides (dimers, trimers etc) comprising the ligand binding domains of cytokines which are linked via flexible polypeptide linker molecules which optionally include protease sensitive sites to modulate the release of biologically active cytokines when administered to an animal.

According to a first aspect of the invention there is provided a polypeptide comprising more than two ligand binding domains of a cytokine receptor wherein said domains are linked by a linker molecule.

10

In a preferred embodiment of the invention at least one linker molecule comprises at least one proteolytic cleavage site. Preferably said cleavage site is sensitive to a serum protease.

15 Preferably said cleavage site comprises the amino acid sequence: LVPRGS, or variant thereof.

In a further preferred embodiment of the invention said cleavage site comprises at least one copy of the amino acid sequence: SGGGG, or functional variant thereof.

20 Preferably, said cleavage site comprises the amino acid sequence PGISGGGGGG.

More preferably still said cleavage site comprises the amino acid sequence: LVPRGS PGISGGGGGG, or variant thereof.

25 Alternatively, said cleavage site comprises at least two copies of the amino acid sequence SGGGG, or functional variant thereof, which flank said cleavage site.

In a further preferred embodiment of the invention said cleavage site is sensitive to the serum protease thrombin.

30

In a further preferred embodiment of the invention said polypeptide comprises a plurality of ligand binding domains. Preferably said polypeptide has 3, 4, 5, 6, 7, 8, 9, or 10 ligand binding domains. Preferably said polypeptide has greater than 10 ligand binding domains.

In a further preferred embodiment of the invention said polypeptide has 4, 6, 8, 10, 12, ligand binding domains.

- 5 In a preferred embodiment of the invention said polypeptide comprises at least four ligand binding domains.

In a further embodiment of the invention said polypeptide is an antagonist.

- 10 In an alternative preferred embodiment of the invention said polypeptide is an agonist.

In a further preferred embodiment of the invention said ligand binding domain is selected from the ligand binding domains of the cytokines selected from the group consisting of: growth hormone; leptin; erythropoietin; prolactin; interleukins (IL), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11; the p35 subunit of IL-12, IL-13, IL-15; granulocyte colony stimulating factor (G-CSF); granulocyte macrophage colony stimulating factor (GM-CSF); ciliary neurotrophic factor (CNTF); cardiotrophin-1 (CT-1); leukemia inhibitory factor (LIF); oncostatin M (OSM); interferon, IFN α and IFN γ .

20

In a preferred embodiment of the invention said ligand binding domain is the ligand binding domain of growth hormone.

25 A single hGH molecule binds to two GHR molecules. The hGH molecule interacts with one receptor molecule through a high affinity site, and with the other through a low affinity site. A single protein chain consisting of hGH linked to hGH will contain two high affinity sites which can bind strongly to a pair of receptor molecules and two low affinity sites.

- 30 In one embodiment of the invention, two or more copies of a ligand binding domain are expressed on a single polypeptide chain and the sequence of the tandem or oligomeric cytokine is arranged 'ligand binding domain-linker-ligand binding domain'.

In a further preferred embodiment of the invention said ligand binding domain is the binding domain of leptin.

- 5 Preferably the linker is a polypeptide which comprises 8 to 40 amino acid residues. More preferably the linker comprises 8 to 24 amino acid residues.

Most preferably the linker comprises at least one copy of the peptide:

- 10 Gly Gly Gly Gly Ser Ser Ser Ser (hereinafter referred to as "Gly4Ser4").

- In one embodiment of the invention the linker is 8 amino acids in length and consists of one copy of the Gly4Ser4 linker. In an alternative embodiment of the invention, the linker is 16 amino acids in length and consists of two copies of the Gly4Ser4
15 linker. In a further alternative embodiment of the invention said linker is 24 amino acids in length and consists of three copies of the Gly4Ser4 linker.

- In an alternative embodiment of the invention, the polypeptide is a fusion protein comprising inframe translational fusions of ligand binding domains according to the
20 invention.

- It will be apparent to one skilled in the art that alternative linkers can be used to link ligand binding domains, for example the use of chemical protein crosslinkers. For example homo-bifunctional crosslinker such as disuccinimidyl-suberimidate-
25 dihydrochloride; dimethyl-adipimidate-dihydrochloride; 1,5,-2,4 dinitrobenzene or hetero-bifunctional crosslinkers such as N-hydroxysuccinimidyl 2, 3-dibromopropionate; 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride; succinimidyl 4-[n-maleimidomethyl]-cyclohexane-1-carboxylate.

- 30 Further examples of chemical crosslinks include the provision of chemically modified linker molecules and/or ligand binding domains. For example, if one end of the linker molecule is terminated with an amino terminal lysine residue and the ligand binding with a carboxyl-terminal glutamine residue then ligand binding domains can be oligomerised with transglutaminase.

According to a further aspect of the invention there is provided a nucleic acid molecule comprising a nucleic acid sequence which encodes a polypeptide according to the invention.

- 5 In a preferred embodiment of the invention said nucleic acid molecule comprises a nucleic acid sequence selected from the group consisting of:
- i) a sequence represented by Figs 4c or 6c;
 - ii) a sequence which hybridises to the sequence of (i) above and which has cytokine receptor modulating activity; and
 - 10 iii) a sequence which is degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above.

In a preferred embodiment of the invention said nucleic acid hybridises under stringent hybridisation conditions to the sequences represented in Figs 4c or 6c.

- 15 It is well known in the art that optimal hybridisation conditions can be calculated if the sequence of the nucleic acid is known. For example, hybridisation conditions can be determined by the GC content of the nucleic acid subject to hybridisation. Please see Sambrook et al (1989) Molecular Cloning; A Laboratory Approach. A common formula for calculating the stringency conditions required to achieve hybridisation between nucleic acid molecules of a specified homology is:

20
$$T_m = 81.5^{\circ} \text{C} + 16.6 \text{ Log } [\text{Na}^+] + 0.41 [\% \text{ G} + \text{C}] - 0.63 (\% \text{ formamide}).$$

- Typically, hybridisation conditions uses 4 – 6 x SSPE (20x SSPE contains 175.3g NaCl, 88.2g $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ and 7.4g EDTA dissolved to 1 litre and the pH adjusted to 7.4); 5-10x Denhardt's solution (50x Denhardt's solution contains 5g Ficoll (type 400, Pharmacia), 5g polyvinylpyrrolidone and 5g bovine serum albumen/500ml; 100µg-1.0mg/ml sonicated salmon/herring DNA; 0.1-1.0% sodium dodecyl sulphate; optionally 40-60% deionised formamide. Hybridisation temperature will vary
- 25

depending on the GC content of the nucleic acid target sequence but will typically be between 42⁰ - 65⁰ C.

According to a further aspect of the invention there is provided a polypeptide which is encoded by a nucleic acid molecule according to the invention.

- 5 In a preferred embodiment of the invention the polypeptide so encoded is modified by deletion, addition or substitution of at least one amino acid residue. Ideally said modification enhances the antagonistic or agonistic effects of said polypeptide with respect to the inhibition or activation of receptor mediated cell signalling.

Alternatively, or preferably, said modification includes the use of modified amino
10 acids in the production of recombinant or synthetic forms of polypeptides.

It will be apparent to one skilled in the art that modified amino acids include, by way of example and not by way of limitation, 4-hydroxyproline, 5-hydroxylysine, N⁶-acetyllysine, N⁶-methyllysine, N⁶,N⁶-dimethyllysine, N⁶,N⁶,N⁶-trimethyllysine, cyclohexylalanine, D-amino acids, ornithine. The incorporation of modified amino
15 acids may confer advantageous properties on polypeptides. For example, the incorporation of modified amino acids may increase the affinity of the polypeptide for its binding site, or the modified amino acids may confer increased *in vivo* stability on the polypeptide thus allowing a decrease in the effective amount of therapeutic polypeptide administered to a patient.

- 20 According to a yet further aspect of the invention there is provided a vector including a DNA molecule according to any preceding aspect or embodiment of the invention.

In a preferred embodiment of the invention said vector is provided with means to recombinantly manufacture the polypeptide of the invention.

25

In a preferred embodiment of the invention said vector is an expression vector adapted for prokaryotic gene expression.

Prokaryotic expression systems are well known in the art and comprise vectors
30 adapted for high level constitutive and inducible expression. Inducible expression systems are particularly advantageous if the recombinant polypeptide is toxic to the

bacterial cell. Induction of expression is tightly regulated by promoters responsive to various inducers (eg IPTG inducible). Bacterial cells can be grown to stationary phase before induction thereby reducing harmful effects of toxic polypeptides.

- 5 Additionally it is also well known in the art that certain polypeptides are difficult to manufacture recombinantly due, for example, to protein instability or problems of aggregation. It is well known that genetically modified bacterial strains are available which are mutated in genes (eg bacterial proteases) which facilitate the production of native and recombinant bacterial polypeptides.

10

In a further preferred embodiment of the invention said vector is an expression vector adapted for eukaryotic gene expression.

- 15 Typically said adaptation includes, by example and not by way of limitation, the provision of transcription control sequences (promoter sequences) which mediate cell/tissue specific expression. These promoter sequences may be cell/tissue specific, inducible or constitutive.

- 20 Promoter is an art recognised term and, for the sake of clarity, includes the following features which are provided by example only, and not by way of limitation. Enhancer elements are *cis* acting nucleic acid sequences often found 5' to the transcription initiation site of a gene (enhancers can also be found 3' to a gene sequence or even located in intronic sequences and are therefore position independent). Enhancers function to increase the rate of transcription of the gene to which the enhancer is
- 25 linked. Enhancer activity is responsive to *trans* acting transcription factors (polypeptides) which have been shown to bind specifically to enhancer elements. The binding/activity of transcription factors (please see Eukaryotic Transcription Factors, by David S Latchman, Academic Press Ltd, San Diego) is responsive to a number of environmental cues which include, by example and not by way of limitation,
- 30 intermediary metabolites (eg glucose, lipids), environmental effectors (eg light, heat).

Promoter elements also include so called TATA box and RNA polymerase initiation selection (RIS) sequences which function to select a site of transcription initiation.

These sequences also bind polypeptides which function, *inter alia*, to facilitate transcription initiation selection by RNA polymerase.

Adaptations also include the provision of selectable markers
5 and autonomous replication sequences which both facilitate the maintenance of said vector in either the eukaryotic cell or prokaryotic host. Vectors which are maintained autonomously are referred to as episomal vectors.

Adaptations which facilitate the expression of vector encoded genes include the
10 provision of transcription termination/polyadenylation sequences. This also includes the provision of internal ribosome entry sites (IRES) which function to maximise expression of vector encoded genes arranged in bicistronic or multi-cistronic expression cassettes.

15 These adaptations are well known in the art. There is a significant amount of published literature with respect to expression vector construction and recombinant DNA techniques in general. Please see, Sambrook et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory, Cold Spring Harbour, NY and references therein; Marston, F (1987) DNA Cloning Techniques: A Practical
20 Approach Vol III IRL Press, Oxford UK; DNA Cloning: F M Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons, Inc.(1994).

In yet a further aspect of the invention there is provided a method to prepare a polypeptide according to the invention comprising:

25

- (i) growing a cell transformed or transfected with a nucleic acid or vector of the present invention in conditions conducive to the manufacture of said polypeptide; and
- (ii) purifying said polypeptide from said cell, or its growth environment.

30

In a preferred method of the invention said vector encodes, and thus said recombinant polypeptide is provided with, a secretion signal to facilitate purification of said binding agent polypeptide.

In yet a further aspect of the invention there is provided a cell transformed/transfected with the vector or nucleic acid according to the invention.

Preferably said cell eukaryotic and is selected from: fungal; insect (eg *Spodoptera frugiperda*); amphibian; plant; mammalian.

More preferably said cell is prokaryotic and is an *E.coli* cell.

According to a further aspect of the invention there is provided the use of the polypeptide according to the invention as a pharmaceutical. Preferably there is provided a pharmaceutical composition comprising the polypeptide according to the invention. Preferably said pharmaceutical composition includes a carrier, excipient and/or a diluent.

In a further preferred embodiment of the present invention said polypeptide is used for the manufacture of a medicament for use in the treatment of a disease selected from the group consisting of: acromegaly; gigantism; Turners syndrome; renal failure; osteoporosis; obesity; insulin resistance; hyperlipidaemia; hypertension; anaemia.

The invention also provides for a method of treating a human or animal subject comprising administering an effective amount of the polypeptide, pharmaceutical composition or medicament to said subject.

When administered, the therapeutic compositions of the present invention are administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, and chemotherapeutic agents.

The polypeptides or compositions of the invention can be administered by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal

The pharmaceutical compositions used in the foregoing methods preferably are sterile and contain an effective amount of the polypeptide according to the invention for producing the desired response in a unit of weight or volume suitable for administration to a patient.

5

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions. The term "pharmaceutically acceptable" means a non-toxic material
10 that does not interfere with the effectiveness of the biological activity of the active ingredients. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents.

15 Compositions may be combined, if desired, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is
20 combined to facilitate the application.

The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.

25

The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.

30 The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association

with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

5 Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.

10 Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of polypeptides which is preferably isotonic with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 15 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for oral, subcutaneous, intravenous, 20 intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.

25 According to a further aspect of the invention there is provide a method of treatment comprising administering to an animal, preferably a human, an effective amount of the nucleic acid or vector according to the invention.

An embodiment of the invention will now be described by example only and with reference to the following figures wherein;

30 Figure 1 illustrates a plasmid map of pTrcHis χ 1A1;

Figure 2 illustrates primers used in the synthesis of the GH-tandem constructs;

Figure 3 is a schematic diagram for the construction of pTrcHis χ 1C1. pTrcHis χ 1C2 is constructed in the same way, however the forward primer used is DiGHNotF and the restriction enzymes used are *NotI* and *HindIII*;

5

Figure 4 illustrates the DNA sequence for growth hormone tandem segregated by a thrombin cleavable linker. The linker region is shown in italics, with the thrombin cleavage site in bold;

10 Figure 5 illustrates the protein sequence for growth hormone tandem segregated by a thrombin cleavable linker. The linker region is shown in italics, with the thrombin cleavage site in bold;

Figure 6 illustrates the DNA sequence for leptin tandem segregated by a thrombin
15 cleavable linker. The linker region is shown in italics, with the thrombin cleavage site in bold; and

Figure 7 illustrates the protein sequence for leptin tandem segregated by a thrombin
20 cleavable linker. The linker region is shown in italics, with the thrombin cleavage site in bold. The cleavable linker is optional in this construct.

Materials and Methods

25 The sequence encoding GHR in pTrcHis χ 1A1 (Fig. 1) was replaced with another GH gene (residues 1-191) to produce two successive GH genes linked with a (G₄S)₄ linker. The resultant construct (pTrcHis χ 1C1) was transformed into *E. coli* XL1 Blue cells. Clones expressing GH-(G₄S)₄-GH protein were identified by western blotting using anti-GH (10A7, mouse IgG1) probed with Sheep anti-mouse-HRP (Amersham).
30 Another GH-tandem, which lacked the (G₄S)₄ linker (GH-GH) was also constructed (pTrcHis χ 1C2) using the same method.

GH-tandem protein was purified from cell lysates using a His-affinity column (Probond resin, Invitrogen) followed by an ion exchange column (MonoQ, Pharmacia).

- 5 The effect of the GH-tandem proteins were analysed using an established bioassay (Ross *et al.*, 1997).

Cloning

- 10 PCR was used to produce a fragment of DNA which consisted of a restriction site (*NotI* or *EcoRI*), followed by the GH gene and then a *HindIII* restriction site. This was ligated into pTrcHis χ 1A1, which had been digested with the relevant restriction enzymes, to produce the constructs χ 1C1 (GH-(G4S)4-GH) and χ 1C2 (GH-GH). The primers used for the PCR's are shown in Fig 2, and the reaction scheme is shown in
15 Fig 3.

Purification of GH-Tandems

- Induced cells (resuspended in 20mM sodium phosphate buffer, 500mM sodium
20 chloride, pH 7.8) were lysed with a combination of 100 μ g/ml (final concentration) hen egg white lysozyme and sonication. Insoluble material was removed by centrifugation at 4000rpm for 20 minutes.

- The cleared cell lysate was applied to a 5ml Probond resin column (Invitrogen),
25 equilibrated with 20mM sodium phosphate buffer, 500mM sodium chloride, 5% glycerol, pH 7.8. The column was then washed with 10 column volumes of 20mM sodium phosphate buffer, 500mM sodium chloride, 5% glycerol, pH 6.0. Bound protein was eluted using 5ml 20mM sodium phosphate buffer, 500mM sodium chloride, 5% glycerol, 500mM imidazole, pH 6.0.

30

The protein was dialysed overnight against Low Salt Buffer (25mM TRIS, 1mM EDTA, 5% glycerol, pH 8.0) and then centrifuged to remove any particulate matter.

The protein sample was then loaded onto a Mono-Q column (Pharmacia), which had been pre-equilibrated with Low Salt Buffer. After a 10 column volume wash with

Low Salt Buffer, the bound proteins were eluted over 20 column volumes using a gradient between 0M sodium chloride to 1M sodium chloride (in 25mM TRIS, 1mM EDTA, 5% glycerol, pH8.0). Peaks on the elution profile were analysed by SDS-PAGE and western blotting.

5

GH-tandem protein was then concentrated (if required) using a Amicon Centriprep Y-10 column.

10

15

20

25

30

REFERENCES

- ARGETSINGER, L.S. & CARTER-SU, C. (1996) Growth hormone signalling mechanisms: involvement of the tyrosine kinase JAK2. [Review] [19 refs].
5 *Hormone Research*, **45 Suppl 1**, 22-24.
- CHEN, C., BRINKWORTH, R. & WATERS, M.J. (1997) The role of receptor dimerization domain residues in growth hormone signaling. *Journal of Biological Chemistry*, **272**, 5133-5140.
- CHEN, W.Y., CHEN, N.Y., YUN, J., WAGNER, T.E. & KOPCHICK, J.J. (1994) In
10 vitro and in vivo studies of antagonistic effects of human growth hormone analogs [published erratum appears in J Biol Chem 1994 Aug 12;269(32):20806]. *Journal of Biological Chemistry*, **269**, 15892-15897.
- CHEN, W.Y., WHITE, M.E., WAGNER, T.E. & KOPCHICK, J.J. (1991) Functional
15 antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice. *Endocrinology*, **129**, 1402-1408.
- CHEN, W.Y., WIGHT, D.C., MEHTA, B.V., WAGNER, T.E. & KOPCHICK, J.J. (1991) Glycine 119 of bovine growth hormone is critical for growth-promoting activity. *Molecular Endocrinology*, **5**, 1845-1852.
- CHEN, W.Y., WIGHT, D.C., WAGNER, T.E. & KOPCHICK, J.J. (1990) Expression
20 of a mutated bovine growth hormone gene suppresses growth of transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*, **87**, 5061-5065.
- CLACKSON, T., ULTSCH, M.H., WELLS, J.A. & DE VOS, A.M. (1998) Structural
25 and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. *Journal of Molecular Biology*, **277**, 1111-1128.
- CUNNINGHAM, B.C., ULTSCH, M., DE VOS, A.M., MULKERRIN, M.G., CLAUSER, K.R. & WELLS, J.A. (1991) Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule.
30 *Science*, **254**, 821-825.

- DE VOS, A.M., ULTSCH, M. & KOSSIAKOFF, A.A. (1992) Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. *Science*, **255**, 306-312.
- 5 FUH, G., CUNNINGHAM, B.C., FUKUNAGA, R., NAGATA, S., GOEDDEL, D.V. & WELLS, J.A. (1992) Rational design of potent antagonists to the human growth hormone receptor. *Science*, **256**, 1677-1680.
- 10 HANIU, M., ARAKAWA, T., BURES, E.J., YOUNG, Y., HUI, J.O., ROHDE, M.F., WELCHER, A.A. & HORAN, T. (1998) Human leptin receptor. Determination of disulfide structure and N-glycosylation sites of the extracellular domain. *Journal of Biological Chemistry*, **273**, 28691-28699.
- HIROIKE, T., HIGO, J., JINGAMI, H. & TOH, H. (2000) Homology modeling of human leptin/leptin receptor complex. *Biochemical & Biophysical Research Communications*, **275**, 154-158.
- 15 HUKSHORN, C.J., SARIS, W.H., WESTERTERP-PLANTENGA, M.S., FARID, A.R., SMITH, F.J. & CAMPFIELD, L.A. (2000) Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. [see comments]. *Journal of Clinical Endocrinology & Metabolism*, **85**, 4003-4009.
- 20 KISHIMOTO, T., TAGA, T. & AKIRA, S. (1994) Cytokine signal transduction. [Review] [92 refs]. *Cell*, **76**, 253-262.
- LIVNAH, O., STURA, E.A., MIDDLETON, S.A., JOHNSON, D.L., JOLLIFFE, L.K. & WILSON, I.A. (1999) Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. *Science*, **283**, 987-990.
- 25 MAAMRA, M., FINIDORI, J., VON LAUE, S., SIMON, S., JUSTICE, S., WEBSTER, J., DOWER & ROSS, R. (1999) Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling. *Journal of Biological Chemistry*, **274**, 14791-14798.

- MELLADO, M., RODRIGUEZ-FRADE, J.M., KREMER, L., VON KOBBE, C., DE ANA, A.M., MERIDA, I. & MARTINEZ, A. (1997) Conformational changes required in the human growth hormone receptor for growth hormone signaling. *Journal of Biological Chemistry*, **272**, 9189-9196.
- 5 ROSS, R.J., ESPOSITO, N., SHEN, X.Y., VON LAUE, S., CHEW, S.L., DOBSON, P.R., POSTEL-VINAY, M.C. & FINIDORI, J. (1997) A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. *Molecular Endocrinology*, **11**, 265-273.
- 10 SUNDSTROM, M., LUNDQVIST, T., RODIN, J., GIEBEL, L.B., MILLIGAN, D. & NORSTEDT, G. (1996) Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 Å resolution. *Journal of Biological Chemistry*, **271**, 32197-32203.
- 15 SYED, R.S., REID, S.W., LI, C., CHEETHAM, J.C., AOKI, K.H., LIU, B., ZHAN, H., OSSLUND, T.D., CHIRINO, A.J., ZHANG, J., FINER-MOORE, J., ELLIOTT, S., SITNEY, K., KATZ, B.A., MATTHEWS, D.J., WENDOLOSKI, J.J., EGRIE, J. & STROUD, R.M. (1998) Efficiency of signalling through cytokine receptors depends critically on receptor orientation. *Nature*, **395**, 511-516.
- 20 THORNER, M.O., STRASBURGER, C.J., WU, Z., STRAUME, M., BIDLINGMAIER, M., PEZZOLI, S., ZIB, K., SCARLETT, J.C. & BENNETT, W.F. (1999) Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. *Journal of Clinical Endocrinology & Metabolism*, **84**, 2098-2103.
- 25




Fig. 1: A plasmid map of pTrcHis χ 1A1.

Name	5'—Sequence—3'
DiGHEco F	AGGCGAATTCTTCCCAACCATTCCCTAT
DiGHNot F	CTTCAAGAGGCGGCGCCGCTTCCCAACCATT CCCTTAT
DiGHHin R	TTCCAAGCTTCATCAGAAGCCACAGCTGCCCT CCA

Fig. 2: Primers used in the synthesis of the GH-tandem constructs.




Fig. 3: Schematic diagram for the construction of pTrcHis χ 1C1. pTrcHis χ 1C2 is constructed in the same way, however the forward primer used is DiGHNotF and the restriction enzymes used are NotI and HindIII.

Figure 4

a) Growth hormone molecule 1

TTCCCAACCATTCCTTATCCAGGCTTTTTGACAACGCTAGTCTCCGCGC
CCATCGTCTGCACCAGCTGGCCTTTGACACCTACCAGGAGTTTGAAGAAG
CCTATATCCCAAAGGAACAGAAGTATTCATTCTGCAGAACCCCCAGACC
TCCCTCTGTTTCTCAGAGTCTATTCCGACACCCTCCAACAGGGAGGAAAC
ACAACAGAAATCCAACCTAGAGCTGCTCCGCATCTCCCTGCTGCTCATCC
AGTCGTGGCTGGAGCCCGTGCAGTTCCTCAGGAGTGTCTTCGCCAACAGC
CTGGTGTACGGCGCCTCTGACAGCAACGTCTATGACCTCCTAAAGGACCT
AGAGGAAGGCATCCAAACGCTGATGGGGAGGCTGGAAGATGGCAGCCCCC
GGACTGGGCAGATCTTCAAGCAGACCTACAGCAAGTTCGACACAAACTCA
CACAACGATGACGCACTACTCAAGAACTACGGGCTGCTCTACTGCTTCAG
GAAGGACATGGACAAGGTCGAGACATTCTGCGCATCGTGCAGTGCCGCT
CTGTGGAGGGCAGCTGTGGCTTC

Linker region

b) *TTAGTGCCGCGCGGCAGTCCGGGCATTGGCGGCGGTGGCGGC*

c) Growth hormone molecule 2

TTCCCAACCATTCCTTATCCAGGCTTTTTGACAACGCTAGTCTCCGCGC
CCATCGTCTGCACCAGCTGGCCTTTGACACCTACCAGGAGTTTGAAGAAG
CCTATATCCCAAAGGAACAGAAGTATTCATTCTGCAGAACCCCCAGACC
TCCCTCTGTTTCTCAGAGTCTATTCCGACACCCTCCAACAGGGAGGAAAC
ACAACAGAAATCCAACCTAGAGCTGCTCCGCATCTCCCTGCTGCTCATCC
AGTCGTGGCTGGAGCCCGTGCAGTTCCTCAGGAGTGTCTTCGCCAACAGC
CTGGTGTACGGCGCCTCTGACAGCAACGTCTATGACCTCCTAAAGGACCT
AGAGGAAGGCATCCAAACGCTGATGGGGAGGCTGGAAGATGGCAGCCCCC
GGACTGGGCAGATCTTCAAGCAGACCTACAGCAAGTTCGACACAAACTCA
CACAACGATGACGCACTACTCAAGAACTACGGGCTGCTCTACTGCTTCAG
GAAGGACATGGACAAGGTCGAGACATTCTGCGCATCGTGCAGTGCCGCT
CTGTGGAGGGCAGCTGTGGCTTC

Figure 5

a) Growth hormone molecule 1

FPTIPLSRLFDNASLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQT
SLCFSESIPSPNRBETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANS
LVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNS
HNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF

b) Linker region

LVPRGS PGIGGGGG

c) Growth hormone molecule 1

FPTIPLSRLFDNASLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQT
SLCFSESIPSPNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANS
LVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNS
HNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF

Figure 6

a) Leptin molecule 1

GTGCCCATCCAAAAAGTCCAAGATGACACCAAAACCCTCATCAAGACAAT
TGTCACCAGGATCAATGACATTTACACACGCGAGTCAGTCTCCTCCAAAC
AGAAAGTCACCGGTTTGGACTTCATTCTGGGCTCCACCCCATCCTGACC
TTATCCAAGATGGACCAGACACTGGCAGTCTACCAACAGATCCTCACCAG
TATGCCTTCCAGAAACGTGATCCAAATATCCAACGACCTGGAGAACCTCC
GGGATCTTCTTCACGTGCTGGCCTTCTCTAAGAGCTGCCACTTGCCCTGG
GCCAGTGGCCTGGAGACCTTGGACAGCCTGGGGGGTGTCTTGGAAGCTTC
AGGCTACTCCACAGAGGTGGTGGCCCTGAGCAGGCTGCAGGGGTCTCTGC
AGGACATGCTGTGGCAGCTGGACCTCAGCCCTGGGTGC

b) Linker region

TTAGTGCCGCGCGGCAGTCCGGGCATTGGCGGCGGTGGCGGC

c) Leptin molecule 2

GTGCCCATCCAAAAAGTCCAAGATGACACCAAAACCCTCATCAAGACAAT
TGTCACCAGGATCAATGACATTTACACACGCGAGTCAGTCTCCTCCAAAC
AGAAAGTCACCGGTTTGGACTTCATTCTGGGCTCCACCCCATCCTGACC
TTATCCAAGATGGACCAGACACTGGCAGTCTACCAACAGATCCTCACCAG
TATGCCTTCCAGAAACGTGATCCAAATATCCAACGACCTGGAGAACCTCC
GGGATCTTCTTCACGTGCTGGCCTTCTCTAAGAGCTGCCACTTGCCCTGG
GCCAGTGGCCTGGAGACCTTGGACAGCCTGGGGGGTGTCTTGGAAGCTTC
AGGCTACTCCACAGAGGTGGTGGCCCTGAGCAGGCTGCAGGGGTCTCTGC
AGGACATGCTGTGGCAGCTGGACCTCAGCCCTGGGTGCTTAGTGCCG

Figure 7

a) Leptin molecule 1

VPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILT
LSKMDQTLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHL
PWASGLETLDLGGVLEASGYSTEVALSRLQGSQDMLWQLDLSPGC

b) Linker region

LVPRGS PGIGGGGG

c) Leptin molecule 2

VPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILT
LSKMDQTLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHL
PWASGLETLDLGGVLEASGYSTEVALSRLQGSQDMLWQLDLSPGC

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.